Moderna "COVID-19 Vaccine Phase 3 Results Show 94.1% Effectiveness"

[Image source=Yonhap News]

[Asia Economy Reporter Kiho Sung] Moderna has begun the process of obtaining approval for the use of its COVID-19 vaccine in the United States and Europe.

According to foreign media on the 30th (local time), Moderna announced that the results of its Phase 3 clinical trial showed an efficacy of 94.1%. Along with this, the company revealed plans to apply for emergency use authorization from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) on the same day.

Moderna explained that the vaccine demonstrated 100% effectiveness in preventing severe COVID-19 symptoms and that no serious safety issues were found.

Tal Zaks, Moderna's Chief Medical Officer (CMO), said, "Our vaccine is highly effective, and we have the data to prove it," adding, "We expect the vaccine to play a crucial role in turning the tide of the COVID-19 pandemic."

Moderna stated that it expects to produce 20 million doses in the United States within this year and will begin distribution immediately upon approval.